ERBB2 and breast carcinoma: The KATHERINE study demonstrated that T-DM1, when administered as adjuvant therapy to patients with HER2-positive breast cancer who did not achieve pathological complete response (pCR) following neoadjuvant therapy, significantly enhanced invasive disease-free survival (iDFS) compared to trastuzumab.